secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2022-04-26T23:59:59+00:00
Accession:  0001104659-22-050367
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharmaceuticals enters research agreement with Mass General for oxygenation sensor in erectile therapy
--------------------------------------------------------------------------------

- Signed Sponsored Research Agreement and Option Agreement with Wellman Center of Massachusetts General Hospital.
- Goal is to evaluate tissue-specific oxygenation sensor to monitor success of Erectile Device Therapy.
- Option agreement allows Petros to negotiate an exclusive license of the sensor technology for specific human tissues.
- Sensor intended to provide bio-sensor feedback for at-home penile therapy, enhancing existing erectile device therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922050367/0001104659-22-050367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922050367/tm2213617d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-050367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer